{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:57:11Z","timestamp":1768737431136,"version":"3.49.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T00:00:00Z","timestamp":1645142400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["19K08328"],"award-info":[{"award-number":["19K08328"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["16K10073"],"award-info":[{"award-number":["16K10073"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Vacuolated podocytes are the most common form of renal damage in Fabry disease, but other types of renal damage have been reported, such as membranous nephropathy (MN) or IgM nephropathy. Enzyme replacement therapy (ERT) is effective at preventing renal damage, but the nephropathies require appropriate treatment to prevent renal damage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 22-year-old male with Fabry disease presented with proteinuria during ERT with agalsidase-\u03b2 and carbamazepine. He had received the treatment for 10\u200ayears and maintained normal plasma globotryaosylceramide levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Renal biopsy revealed MN without vacuolated podocytes. Immunofluorescent staining of the IgG subclass revealed granular patterns of IgG1, G2, G4, and C3 deposition in the glomerular basement membrane.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The carbamazepine dose was reduced from 600\u200amg\/day to 200\u200amg\/day (serum concentration 10.0-11.0\u20134.0\u20135.0\u200a\u03bcg\/mL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After reducing the carbamazepine dose, proteinuria was negative, and the patient has had a normal urinalysis for 17\u200amonths. Plasma globotryaosylceramide levels have also remained normal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This report is a reminder of the co-existence of MN without vacuolated podocytes in Fabry disease during ERT with agalsidase-\u03b2 and carbamazepine.<\/jats:p>\n            <jats:p>Physicians should be aware of this form of renal damage in Fabry disease, even during treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028830","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T15:08:22Z","timestamp":1648825702000},"page":"e28830","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-\u03b2 and carbamazepine"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9673-6201","authenticated-orcid":false,"given":"Takahiro","family":"Kanai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takane","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Aoyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,2,18]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"R2-20250504","first-page":"48","article-title":"Coexistence of Fabry disease and membranous nephropathy","volume":"10","author":"Liu","year":"2016","journal-title":"Iran J Kidney Dis"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e17566","DOI":"10.1097\/MD.0000000000017566","article-title":"Coexistence of Fabry disease with IgM nephropathy: a case report","volume":"98","author":"Wu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R4-20250504","first-page":"39","article-title":"Foot process effacement with normal urinalysis in classic Fabry disease","volume":"1","author":"Kanai","year":"2011","journal-title":"JIMD Rep"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00431-015-2646-x","article-title":"Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease","volume":"175","author":"Kanai","year":"2016","journal-title":"Eur J Pediatr"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease","volume":"13","author":"Branton","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"611317","DOI":"10.3389\/fmed.2020.611317","article-title":"Secondary membranous nephropathy. A narrative review","volume":"7","author":"Moroni","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: membranous nephropathy\u2013a modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0971-4065.132030","article-title":"Membranous nephropathy and carbamazepine","volume":"24","author":"Sangeetha","year":"2014","journal-title":"Indian J Nephrol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.294.6568.375-a","article-title":"<strong>Drug points<\/strong>: membranous glomerulopathy associated with carbemazepine","volume":"294","author":"Hordon","year":"1987","journal-title":"Br Med J"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2018070740","article-title":"Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody tters and clinical outcome in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J Am Soc Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:22:17Z","timestamp":1746332537000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028830"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,2,18]]},"references-count":11,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028830","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,18]]},"assertion":[{"value":"2022-01-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}